These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 28284845)

  • 1. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
    Maneiro JR; Souto A; Gomez-Reino JJ
    Semin Arthritis Rheum; 2017 Oct; 47(2):149-156. PubMed ID: 28284845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012437. PubMed ID: 27855242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
    Tarp S; Eric Furst D; Boers M; Luta G; Bliddal H; Tarp U; Heller Asmussen K; Brock B; Dossing A; Schjødt Jørgensen T; Thirstrup S; Christensen R
    Rheumatology (Oxford); 2017 Mar; 56(3):417-425. PubMed ID: 28013201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
    Camean-Castillo M; Gimeno-Ballester V; Rios-Sanchez E; Fenix-Caballero S; Vázquez-Real M; Alegre-Del Rey E
    J Clin Pharm Ther; 2019 Jun; 44(3):384-396. PubMed ID: 30729557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC; Zwillich SH; Jansen JP; Smiechowski B; Spurden D; Wallenstein GV
    Clin Ther; 2016 Dec; 38(12):2628-2641.e5. PubMed ID: 27889300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
    Song GG; Choi SJ; Lee YH
    Int J Rheum Dis; 2019 Aug; 22(8):1563-1571. PubMed ID: 31211506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
    Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
    Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis.
    Zhang X; Liang F; Yin X; Xiao X; Shi P; Wei D; Yao L; Wang Q; Chen Y
    Clin Rheumatol; 2014 Feb; 33(2):165-73. PubMed ID: 24389749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies.
    Souto A; Maneiro JR; Salgado E; Carmona L; Gomez-Reino JJ
    Rheumatology (Oxford); 2014 Oct; 53(10):1872-85. PubMed ID: 24821849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of discontinuation rates of tofacitinib and biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: a systematic review and Bayesian network meta-analysis.
    Park SK; Lee MY; Jang EJ; Kim HL; Ha DM; Lee EK
    Clin Exp Rheumatol; 2017; 35(4):689-699. PubMed ID: 28079510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
    Machado MAÁ; Moura CS; Guerra SF; Curtis JR; Abrahamowicz M; Bernatsky S
    Arthritis Res Ther; 2018 Mar; 20(1):60. PubMed ID: 29566769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
    Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
    Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
    Kaur K; Kalra S; Kaushal S
    Clin Ther; 2014 Jul; 36(7):1074-86. PubMed ID: 25047498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
    Curtis JR; Xie F; Yun H; Bernatsky S; Winthrop KL
    Ann Rheum Dis; 2016 Oct; 75(10):1843-7. PubMed ID: 27113415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.